Annotation Detail
Information
- Associated Genes
- KRAS
- Associated Variants
-
KRAS MUTATION
KRAS MUTATION - Associated Disease
- endometrial cancer
- Source Database
- CIViC Evidence
- Description
- 94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed. Mutations were found in 32 of 73 analyzed tumors, 10 of which were KRAS mutations. No predictive biomarkers were identified, including PIK3CA mutations, KRAS mutations or PTEN loss.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/894
- Gene URL
- https://civic.genome.wustl.edu/links/genes/30
- Variant URL
- https://civic.genome.wustl.edu/links/variants/336
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Endometrial Cancer
- Evidence Direction
- Does Not Support
- Drug
- Temsirolimus,Ridaforolimus
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 24166148
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Ridaforolimus | Sensitivity | false |
| Temsirolimus | Sensitivity | false |